The White Room

Home | Contact | Glossary | Login:

Oncology Media Resource from Boehringer Ingelheim

THE WHITE ROOM

My Selection

Boehringer Ingelheim in oncology

Download now

Add to my Selection

Size: 0.35 MB (PDF)

Rating:

You may rate this item by clicking the bulbs

You may rate this item by clicking the bulbs

You may rate this item by clicking the bulbs

You may rate this item by clicking the bulbs

You may rate this item by clicking the bulbs

Boehringer Ingelheim and the search for new targeted cancer treatments

Boehringer Ingelheim

Related Documents

Items: 10

Webcast South Korea, the evolution of lung cancer care

Webcast South Korea, the evolution of lung cancer care

Personalised medicine and the future of oncology treatment

Personalised medicine and the future of oncology treatment

BIBF 1120 and angiogenesis inhibition

BIBF 1120 and angiogenesis inhibition

BIBF 1120 in ovarian cancer

BIBF 1120 in ovarian cancer

Angiokinase inhibitors in lung cancer

Angiokinase inhibitors in lung cancer

Clinical Trials E-Booklet Chapter 4: Defining Progression

Clinical Trials E-Booklet Chapter 4: Defining Progression

LUME Lung 2 clinical trial infographic

LUME Lung 2 clinical trial infographic

Resistance to EGFR TKIs

Resistance to EGFR TKIs

EGFR Mode of Action

EGFR Mode of Action

Epidermal growth factor (EGF) receptors

Epidermal growth factor (EGF) receptors

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

© 2012 Boehringer Ingelheim GmbH. All rights reserved. | Terms of use | Imprint

Boehringer Ingelheim on

Youtube

Digital Communication Award 2011